RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
DiaSorin SpA Stock

DiaSorin SpA Revenue 2024

DiaSorin SpA Revenue

1.2 B EUR

Ticker

DIA.MI

ISIN

IT0003492391

WKN

A0MTB2

In 2024, DiaSorin SpA's sales reached 1.2 B EUR, a 4.6% difference from the 1.15 B EUR sales recorded in the previous year.

The DiaSorin SpA Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2029e1.8739,55
2028e1.7642,14
2027e1.5547,76
2026e1.4152,49
2025e1.357,06
2024e1.261,71
20231.1564,55
20221.3666,17
20211.2466,64
20200.8868,41
20190.7169,19
20180.6768,11
20170.6467,75
20160.5768,35
20150.568,49
20140.4467,32
20130.4368,93
20120.4368,53
20110.4471,34
20100.470,38
20090.370,24
20080.2465,66
20070.263,32
20060.1861,23
20050.1657,96

DiaSorin SpA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into DiaSorin SpA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DiaSorin SpA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DiaSorin SpA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of DiaSorin SpA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into DiaSorin SpA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing DiaSorin SpA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DiaSorin SpA’s growth potential.

DiaSorin SpA Revenue, EBIT and net profit per share

DateDiaSorin SpA RevenueDiaSorin SpA EBITDiaSorin SpA Net Income
2029e1.87 B undefined0 undefined0 undefined
2028e1.76 B undefined566.46 M undefined0 undefined
2027e1.55 B undefined446.43 M undefined346.52 M undefined
2026e1.41 B undefined360.03 M undefined252.21 M undefined
2025e1.3 B undefined313.88 M undefined219.42 M undefined
2024e1.2 B undefined270.72 M undefined187.75 M undefined
20231.15 B undefined237.85 M undefined159.85 M undefined
20221.36 B undefined375.32 M undefined240.91 M undefined
20211.24 B undefined441.4 M undefined310.97 M undefined
2020881.31 M undefined330.11 M undefined247.87 M undefined
2019706.32 M undefined222.46 M undefined175.74 M undefined
2018669.2 M undefined209.85 M undefined158.13 M undefined
2017637.49 M undefined197.56 M undefined139.88 M undefined
2016569.31 M undefined177.94 M undefined112.38 M undefined
2015499.18 M undefined156.07 M undefined100.42 M undefined
2014443.77 M undefined131.59 M undefined84.07 M undefined
2013434.8 M undefined132.4 M undefined83 M undefined
2012433.8 M undefined140.2 M undefined87.4 M undefined
2011440 M undefined163.5 M undefined99.6 M undefined
2010404.5 M undefined151.4 M undefined90.4 M undefined
2009304.1 M undefined105.2 M undefined70 M undefined
2008244.6 M undefined70.7 M undefined37.5 M undefined
2007202.3 M undefined46.1 M undefined25.2 M undefined
2006179.8 M undefined40.2 M undefined22.3 M undefined
2005156.5 M undefined27.3 M undefined10.4 M undefined

DiaSorin SpA stock margins

The DiaSorin SpA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DiaSorin SpA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DiaSorin SpA.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the DiaSorin SpA's sales revenue. A higher gross margin percentage indicates that the DiaSorin SpA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the DiaSorin SpA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the DiaSorin SpA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DiaSorin SpA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DiaSorin SpA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DiaSorin SpA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

DiaSorin SpA Margin History

DiaSorin SpA Gross marginDiaSorin SpA Profit marginDiaSorin SpA EBIT marginDiaSorin SpA Profit margin
2029e64.55 %0 %0 %
2028e64.55 %32.2 %0 %
2027e64.55 %28.76 %22.33 %
2026e64.55 %25.5 %17.86 %
2025e64.55 %24.16 %16.89 %
2024e64.55 %22.54 %15.63 %
202364.55 %20.71 %13.92 %
202266.17 %27.57 %17.7 %
202166.64 %35.66 %25.13 %
202068.41 %37.46 %28.13 %
201969.19 %31.5 %24.88 %
201868.11 %31.36 %23.63 %
201767.75 %30.99 %21.94 %
201668.35 %31.26 %19.74 %
201568.49 %31.27 %20.12 %
201467.32 %29.65 %18.95 %
201368.93 %30.45 %19.09 %
201268.53 %32.32 %20.15 %
201171.34 %37.16 %22.64 %
201070.38 %37.43 %22.35 %
200970.24 %34.59 %23.02 %
200865.66 %28.9 %15.33 %
200763.32 %22.79 %12.46 %
200661.23 %22.36 %12.4 %
200557.96 %17.44 %6.65 %

DiaSorin SpA Aktienanalyse

What does DiaSorin SpA do?

DiaSorin SpA is an Italian medical technology company that specializes in the development and production of diagnostic solutions for serious diseases. The company was founded in 1968 in Saluggia, a small town in the Piedmont region of northern Italy. Since then, DiaSorin has experienced impressive growth and now operates worldwide. DiaSorin is a major player in the in-vitro diagnostics (IVD) market and offers a wide range of solutions for clinical laboratories and medical professionals. The company's business model is based on the development of innovative test systems that enable fast, reliable, and accurate diagnosis of diseases. The company's goal is to provide improved access to diagnostic opportunities for patients worldwide and support the entire medical practice. In its early days, DiaSorin mainly focused on the development and production of enzyme immunoassays (EIAs) and other immunochemical tests. However, over the years, the company has evolved and introduced a variety of product lines, including molecular diagnostic tests, automated immunoassay systems and instruments, and clinical laboratory software. Today, DiaSorin has four main business areas: Immunoassays, Molecular Biology, Automation, and Diagnosis Information Management. The Immunoassays business area, also known as diaMune, offers a wide range of immunoassay solutions based on various technologies, including chemiluminescence, ELISA, fluorescence, and multiplexing. The Molecular Biology business area, also known as DiaMolecular, develops and produces a broad spectrum of molecular diagnostic solutions, including tests for infectious diseases, oncological diseases, and genetic disorders. DiaMolecular's products provide fast, efficient, and highly accurate diagnosis of serious diseases, enabling early treatment and therapy. The third major business area, DiaSorin's automation solutions, offers instruments and automated testing systems that optimize laboratory processes, improve efficiency, and speed up test execution. These solutions not only increase the accuracy and reliability of diagnostic tests but also help reduce costs and workload in medical laboratories. Finally, DiaSorin's Diagnosis Information Management business area offers a variety of software solutions that assist medical professionals in managing and interpreting diagnostic data. These solutions enable faster and more accurate diagnosis and can also contribute to improving patient care and optimizing laboratory processes. DiaSorin is led by a strong and experienced management team committed to driving the company's growth through continuous innovation and expansion into new markets. With branches and subsidiaries around the world, DiaSorin is a key player in the global medical technology industry. Overall, DiaSorin is an innovative and forward-thinking company that continuously develops its technologies and solutions to improve the quality of life for millions of people worldwide. DiaSorin SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding DiaSorin SpA's Sales Figures

The sales figures of DiaSorin SpA originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing DiaSorin SpA’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize DiaSorin SpA's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in DiaSorin SpA’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about DiaSorin SpA stock

How much revenue did DiaSorin SpA generate this year?

DiaSorin SpA has achieved a revenue of 1.2 B EUR this year.

How much was the turnover of the company DiaSorin SpA compared to the previous year?

The revenue of DiaSorin SpA has increased by 4.6% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of DiaSorin SpA?

The revenue of DiaSorin SpA is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of DiaSorin SpA measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of DiaSorin SpA so important for investors?

The revenue of DiaSorin SpA is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does DiaSorin SpA pay?

Over the past 12 months, DiaSorin SpA paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 1.07 %. For the coming 12 months, DiaSorin SpA is expected to pay a dividend of 1.24 EUR.

What is the dividend yield of DiaSorin SpA?

The current dividend yield of DiaSorin SpA is 1.07 %.

When does DiaSorin SpA pay dividends?

DiaSorin SpA pays a quarterly dividend. This is distributed in the months of June, June, June, June.

How secure is the dividend of DiaSorin SpA?

DiaSorin SpA paid dividends every year for the past 0 years.

What is the dividend of DiaSorin SpA?

For the upcoming 12 months, dividends amounting to 1.24 EUR are expected. This corresponds to a dividend yield of 1.2 %.

In which sector is DiaSorin SpA located?

DiaSorin SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von DiaSorin SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DiaSorin SpA from 5/22/2024 amounting to 1.15 EUR, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.

When did DiaSorin SpA pay the last dividend?

The last dividend was paid out on 5/22/2024.

What was the dividend of DiaSorin SpA in the year 2023?

In the year 2023, DiaSorin SpA distributed 1.05 EUR as dividends.

In which currency does DiaSorin SpA pay out the dividend?

The dividends of DiaSorin SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von DiaSorin SpA

Our stock analysis for DiaSorin SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DiaSorin SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.